Comparison
Aars1 Related Leukoencephalopathy Cn379160 vs 2 Hydroxyglutarate Aciduria C5139239
Clinical comparison between Aars1 Related Leukoencephalopathy CN379160 and 2 Hydroxyglutarate Aciduria for differential diagnosis and treatment planning.
Aars1 Related Leukoencephalopathy Cn379160
A rare genetic condition affecting the brain's white matter, caused by mutations in the AARS1 gene. It can cause movement problems, developmental delays, and other neurological symptoms.
2 Hydroxyglutarate Aciduria C5139239
A metabolic disorder causing buildup of 2-hydroxyglutaric acid. It may affect the brain and nervous system. Management includes supportive therapies and monitoring for complications.
6 comparison axes
Onset
Aars1 Related Leukoencephalopathy Cn379160
0-60
2 Hydroxyglutarate Aciduria C5139239
0-10
Onset patterns differ
Severity
Aars1 Related Leukoencephalopathy Cn379160
severe
2 Hydroxyglutarate Aciduria C5139239
moderate
Different severity levels
Chronic
Aars1 Related Leukoencephalopathy Cn379160
Chronic
2 Hydroxyglutarate Aciduria C5139239
Chronic
Differing course
Communicable
Aars1 Related Leukoencephalopathy Cn379160
No
2 Hydroxyglutarate Aciduria C5139239
No
Different transmission
Body System
Aars1 Related Leukoencephalopathy Cn379160
neurologic
2 Hydroxyglutarate Aciduria C5139239
metabolic
Same/different system
Category
Aars1 Related Leukoencephalopathy Cn379160
neurologic
2 Hydroxyglutarate Aciduria C5139239
metabolic
Different category
Bottom line
aars1-related-leukoencephalopathy-CN379160 and 2-hydroxyglutarate-aciduria-C5139239 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Aars1 Related Leukoencephalopathy Cn379160 | 2 Hydroxyglutarate Aciduria C5139239 | Discriminating power |
|---|---|---|---|
| Primary mechanism | AARS1-related disorder affecting brain white matter | Buildup of 2-hydroxyglutaric acid with possible nervous-system effects | High |
| Onset window | Supplied range spans infancy through adulthood, 0–60 | Supplied range is earlier, 0–10 | Moderate |
| Neurologic burden | Movement problems and developmental delay are described; listed as severe | Brain involvement may occur; listed as moderate | Low |
When to favor each condition
Choose Aars1 Related Leukoencephalopathy Cn379160 when
AARS1 variant with compatible leukoencephalopathy
This best matches the named genetic white-matter condition
High
White-matter abnormality without established acid accumulation
Supports consideration, but imaging or genetics alone may not prove it
Moderate
Later childhood or adult neurologic onset
Fits the broader supplied onset range better than the comparison
Low
Choose 2 Hydroxyglutarate Aciduria C5139239 when
Documented 2-hydroxyglutaric acid accumulation
This directly matches the metabolic condition’s defining abnormality
High
Early-childhood metabolic or neurologic presentation
Aligns with the supplied onset range of 0–10
Moderate
Need for metabolic monitoring and supportive care
The source emphasizes monitoring and supportive management
Moderate
How key tests differ
| Test | Aars1 Related Leukoencephalopathy Cn379160 | 2 Hydroxyglutarate Aciduria C5139239 | Interpretation |
|---|---|---|---|
| Genetic testing | A pathogenic or likely pathogenic AARS1 variant may support it | AARS1 is not the defining test; other genes may apply | Specialist review is required; a variant alone may not establish disease |
| Urine organic acids | No specific 2-hydroxyglutarate pattern is established here | Elevated 2-hydroxyglutaric acid is characteristic | An abnormal metabolite result is not by itself a complete diagnosis |
| Brain MRI | White-matter changes may be present | Brain involvement may occur, but no pattern is specified | MRI aids evaluation but cannot reliably separate these conditions alone |
Prognosis comparison
Aars1 Related Leukoencephalopathy Cn379160
- Outcome
- Listed as severe and chronic, but individual outcome is not established.
- Factors
- AARS1 findings, white-matter involvement, and developmental or movement effects.
2 Hydroxyglutarate Aciduria C5139239
- Outcome
- Listed as moderate and chronic; subtype and complications may change the course.
- Factors
- Acid accumulation, neurologic involvement, monitoring, and supportive care.
Time frame: Long-term; survival and milestone data are not supplied.
Confirmed diagnosis, onset age, complications, and specialist care access.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental impairment | Developmental delay is described Possible when the nervous system is affected, but not established as universal Severity and timing vary and are not quantified here |
| Movement difficulty | Movement problems are described Not specifically established in the supplied description Functional impact requires individual clinical assessment |
| Metabolic complications | Not described as a primary metabolic aciduria Monitoring for complications is advised Exact complication types and rates are not supplied |
Patient education highlights
- HighConfirm the diagnosis
These conditions are not interchangeable. Genetic and metabolic results need specialist interpretation.
- HighUrgent changes
Seek urgent care for seizures, breathing difficulty, rapid neurologic decline, or feeding failure.
- MediumSupportive planning
Therapies, developmental services, and follow-up may help. No treatment dose or cure is established here.